ADCs newly into human trials include Lilly's PTK7 and two bispecifics.
ApexOnco Front Page
Recent articles
Bezuclastinib's registrational trial meets predefined success criteria, with a big spotlight on toxicity.
But the overall survival benefit in prostate cancer is still driven by HRR mutations.
Phase 1 data give investors a benchmark for mevrometostat's pivotal Mevpro-1 trial.
AbbVie follows Gilead in throwing Xilio a lifeline.
The deal isn’t done, but would be Merck’s biggest oncology buy.
Padcev still looks good in first-line bladder, but Pfizer hopes to make a mark in muscle-invasive disease.
Orca-T is said to hit in a pivotal trial, but the comparator regimen could be debated.
